Shandong-based China Biologic Products, a leading plasma-related pharmaceutical company in China, has announced that one of its research projects, "High-Purity Human Albumin," will be listed in the National Torch Plan of China.

China Biologic Products, a company producing plasma-based pharmaceuticals, has received approval from the Chinese State Food and Drug Administration to commence clinical trials of its new Human Coagulation Factor VIII product — a coagulation treatment for hemophilia and mass hemorrhaging.

China Biologic Products, one of the leading manufacturers of plasma-based pharmaceutical products in China, has been granted a RMB1.5 million award by the Shandong Provincial Government for use in the improvement of its plasma production facilities in accordance with Shandong's "Double Hundred Project" initiative.